Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor

This publication has 28 references indexed in Scilit:

• A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
  AIDS, 1999
• The Effect of Increasing α₁‐Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease Inhibitors
  The Journal of Infectious Diseases, 1999
• Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection
  The Journal of Infectious Diseases, 1999
• Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
  Clinical Pharmacokinetics, 1999
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
  The Lancet, 1998
• A Computational Study of the Resistance of HIV-1 Aspartic Protease to the Inhibitors ABT-538 and VX-478 and Design of New Analogues
  Biochemical and Biophysical Research Communications, 1998
• Amprenavir
  Drugs, 1998
• Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
  AIDS, 1997
• In Vitro Effect of α₁‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease Inhibitors
  The Journal of Infectious Diseases, 1997
• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
  Antiviral Research, 1996